Biocon Limited · NSE:BIOCON
Biocon — Q2 FY27 Earnings Presentation
18 slides from Biocon's earnings presentation, Nov 4, 2026
Slide 1: Exchange filing cover letter: Presentation – Q2 FY27 Earnings Call
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 E: [email protected] www.biocon.com BIO/SECL/TG/2026-27/81 November 04, 2026 To, To, The Secretary The Secretary BSE Limited National Stock Exchange of In
Slide 2: Biocon Limited Q2 FY27 Earnings Call
Biocon Limited Q2 FY27 Earnings Call 04 – Nov – 2026
Slide 3: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 4: Chairperson's Opening Remarks
Chairperson’s Opening Remarks
Slide 5: Biocon at an Inflection Point: From Investment to Value Creation
Biocon at an Inflection Point: From Investment to Value Creation ▪ Well positioned for structural industry shifts, supported by Biocon’s global Biosimilars platform and Syngene’s integrated research, development and manufacturing capabilities ▪ Transitioning from investment-led capability building t
Slide 6: Expanding Market Presence across Key Geographies
Expanding Market Presence across Key Geographies ▪ North America ❖ Established products continued to demonstrate resilience, with Ogivri® and Fulphila® maintaining leadership positions ❖ Yesintek® sustained its positive momentum, supported by market-share gains and improving access ❖ Yesafili record
Slide 7: MD & CEO Remarks
MD & CEO Remarks
Slide 8: Financial Highlights: Q2 FY27
Financial Highlights: Q2 FY27 In ₹ Cr Q2 FY27 Q2 FY26 Q1 FY27 YoY% QoQ% Biopharmaceuticals 3,583 3,422 3,614 5 (1) - Biosimilars 2,809 2,721 2,855 3 (2) - Generics 774 701* 760 10 2 Services 833 911 736 (9) 13 Revenue from Operations 4,389 4,296 4,336 2 1 Total Revenue 4,423 4,389 4,391 1 1 R&D (Net
Slide 9: Financial Highlights: H1 FY27
Financial Highlights: H1 FY27 In ₹ Cr H1 FY27 H1 FY26 YoY% Biopharmaceuticals 7,200 6,511 11 - Biosimilars 5,664 5,179 9 - Generics 1,536 1,332 15 Services 1,569 1,785 (12) Revenue from Operations 8,725 8,237 6 Total Revenue 8,814 8,410 5 R&D (Net) 477 455 5 % of Revenue (Ex. Syngene) 7 7 EBITDA 1,7
Slide 10: Biosimilars
Biosimilars
Slide 11: Biosimilars: Q2 FY27 Business Performance Update
Biosimilars: Q2 FY27 Business Performance Update Q2 Q2 Q1 ▪ Financial Performance In ₹ Cr YoY% QoQ% FY27 FY26 FY27 ❖ Revenue stood at ₹2,809 Cr Segment 2,809 2,721 2,855 3 (2) ❖ EBITDA stood at ₹623 Cr; 22% margin Revenue R&D 202 180 192 12 5 ❖ Reported growth & margins impacted by timing of revenue
Slide 12: Generics
Generics
Slide 13: Generics: Q2 FY27 Business Performance Update
Generics: Q2 FY27 Business Performance Update Q2 Q2 Q1 ▪ Financial Performance In ₹ Cr YoY% QoQ% FY27 FY26* FY27 ❖ Revenues grew 10% YoY Segment 774 701 760 10 2 ❖ EBITDA margin expanded by over 700bps YoY Revenue ❖ Improved capacity utilization, operating leverage and R&D 35 71 47 (51) (26) product
Slide 14: Services
Services
Slide 15: Services: Q2 FY27 Business Performance Update
Services: Q2 FY27 Business Performance Update ▪ Financial Performance In ₹ Cr Q2 FY27 Q2 FY26 Q1 FY27 YoY% QoQ% ❖ Revenue stood at ₹833 Cr, up 13% QoQ ❖ EBITDA margin improved by 500bps QoQ Segment 833 911 736 (9) 13 Revenue ❖ Sequential improvement reflects benefits from corrective actions and cost
Slide 16: Concluding Remarks
Concluding Remarks
Slide 17: Concluding Remarks: Q2 FY27
Concluding Remarks: Q2 FY27 ▪ Stronger H2 expected, supported by Biosimilars launch momentum and enhanced insulins capacity, continued Generics profitability improvement and a progressive recovery in Services ▪ Focused on translating growth into improved margins, free cash flow, debt reduction and h
Slide 18: Thank you Q&A
SCIENCE FOR PEOPLE ADVANCING IMPACT Q&A